The significance of p53 autoantibodies in the serum of patients with breast cancer

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 927-930

  Willsher, P C ^a   Pinder, S E ^a   Robertson, L ^b   Nicholson, R I ^c   Ellis, I O ^a   Bell, J A ^a   Blamey, R W ^a   Green, J A ^b   Robertson, J F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b CLATTERBRIDGE HOSPITAL   (United Kingdom)

^c Tenovus Institute   (United Kingdom)

Author keywords

Autoantibodies; Breast cancer; p53; Tumour markers

Indexed keywords

AUTOANTIBODY; ESTROGEN RECEPTOR; PROTEIN P53; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTIBODIES, NEOPLASM; AUTOANTIBODIES; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029941452     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Thor A, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845-854, 1992.
2. Elledgc RM, Fuqua SAW, Clark GM, Pujol P, Alldred DC, Me Guire WL: Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 26: 225-235, 1993.
3. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403-408, 1982.
4. Schlichtholz B, Legros Y, Gillet D, Galliard C, Marty M, Lane D, Calvo F, Soussi T The immune response to p53 in breast cancer patients is directed immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380-6384, 1992.
5. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207-2191, 1992.
6. Mudenda B, Green JA Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ: The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69: 1115-1119, 1994.
7. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer, J. The value of histological grade in breast cancer: experience in a large study with long term follow-up. Histopathology 19: 403-410, 1991.
8. Robertson JFR Bates K Pearson D, Blamey RW, Nicholson RN: Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 65: 727-730, 1990.
9. Oliner JD, Kinzler KW, Meltzer PS, George DL. Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992.
10. Schlichtholz B, Tredaniel J, Lubin R, Zalcman A, Hirsch A, Soussi T: Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69: 809-816, 1994.
11. Davidoff AM, Iglehart JD, Marks JR: Immune response to p53 is dependent upon p53\HSP70 complexes in breast cancer. Proc Natl Acad Sci 89: 3439-3442, 1992.
12. Porsolt F, Schmid M, Hoher D, Muche R, Gaus W, Montenarh M: Biological relevance of auto-antibodies against p53 in patients with metastatic breast cancer. Onkologie 17: 402-408, 1994.
13. Pyret J-P, Bonneterre J, Lubin R, Vanlemmens L, Foumier J, Soussi: Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. The Lancet 345: 621-622, 1995.
14. Bartek J, Bartkova J, Vojtesek B. Patterns of expression of the p53 tumour suppressor in human breast tissues in situ and in vitro. Int J Cancer 46: 839-844, 1990.
15. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in Breast Cancer. Int J Cancer 41: 178-183, 1988.
16. Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, Blarney RW, Ellis IO- p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein over expression, and oestrogen receptor. Br J Cancer 66: 583-588, 1992.
17. Morkve O, Laerum OD: Flowcytometric measurement of p53 protein expression and DNA content in paraffin embedded tissue from bronchial carcinomas. Cytometry 12: 438-444, 1991.
18. Cattoretti G, Andreola S, Clemente C, D'Amato L, Rilke F. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer 57: 353-357, 1988.